Literature DB >> 6875862

Correlation between cholinesterase inhibition and reduction in muscarinic receptors and choline uptake by repeated diisopropylfluorophosphate administration: antagonism by physostigmine and atropine.

S Yamada, M Isogai, H Okudaira, E Hayashi.   

Abstract

Muscarinic receptors, [14C]choline uptake and acetylcholinesterase (AChE) activity in central and peripheral tissues of guinea-pigs treated repeatedly with diisopropylfluorophosphate (DFP) were simultaneously determined. After repeated DFP (1 mg/kg) administration, there was a significant decrease in specific [3H] quinuclidinyl benzilate binding only in the striatum, ileal longitudinal muscle and urinary bladder among various tissues examined. Scatchard analysis revealed that the administration of DFP at 0.5, 1 and 2 mg/kg which depressed the tissue AChE by 50 to 90%, caused a dose-dependent decrease (20-50%) in striatal and ileal [3H]quinuclidinyl benzilate binding sites without a change in the dissociation constant. The lower dose (0.2 mg/kg) of DFP depressed significantly the AChE in both tissues by 30% but failed to alter their [3H]quinuclidinyl benzilate binding sites. High affinity uptake of [14C]choline in the striatum and ileal longitudinal muscle was significantly decreased by repeated administration of DFP at 0.5 and 1 mg/kg but not 0.2 mg/kg. The DFP-induced loss of striatal and ileal muscarinic receptors was effectively antagonized by a concomitant administration of physostigmine (0.5 mg/kg) and atropine (5 mg/kg). Also, these drugs antagonized the DFP-induced decrease in the striatal [14C]choline uptake. Thus, the present study has demonstrated that repeated DFP administration causes a specific decrease in muscarinic receptors and [14C]choline uptake in the striatum and ileal longitudinal muscle of guinea pigs which is closely associated with a considerable (more than 50%) depression of the tissue AChE. In addition, these adaptive changes by DFP were effectively antagonized by physostigmine and atropine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6875862

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  The oxime HGG-12 as a muscarinic acetylcholine receptor antagonist without intrinsic activity in cardiac membranes.

Authors:  C Reithmann; H J Berger; G Hilf; K Werdan
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

2.  Action of an irreversible acetylcholine esterase inhibitor, soman, on muscarinic hyperpolarization in cat bladder parasympathetic ganglia.

Authors:  E Kumamoto; P Shinnick-Gallagher
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

3.  Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice.

Authors:  Yoshihiko Ito; Luvsandorj Oyunzul; Masanao Seki; Tomomi Fujino Oki; Minoru Matsui; Shizuo Yamada
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

4.  Pharmacological adaptations and muscarinic receptor plasticity in hypothalamus of senescent rats treated chronically with cholinergic drugs.

Authors:  N W Pedigo
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Distribution of 3H-soman in mice.

Authors:  T Kadar; L Raveh; G Cohen; N Oz; I Baranes; A Balan; Y Ashani; S Shapira
Journal:  Arch Toxicol       Date:  1985-10       Impact factor: 5.153

6.  Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters.

Authors:  J M Gearhart; G W Jepson; H J Clewell; M E Andersen; R B Conolly
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

7.  Acetylcholine Neurotransmitter Receptor Densities in the Striatum of Hemiparkinsonian Rats Following Botulinum Neurotoxin-A Injection.

Authors:  Teresa Mann; Karl Zilles; Felix Klawitter; Markus Cremer; Alexander Hawlitschka; Nicola Palomero-Gallagher; Oliver Schmitt; Andreas Wree
Journal:  Front Neuroanat       Date:  2018-08-10       Impact factor: 3.856

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.